Form 4 for CRL Charles River Laboratories
Accepted 2026-08-13 16:37:36 ET · period of report 2026-08-11 · accession 0001100682-26-000132 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2026-08-13 16:37 | 2026-08-11 | CRL | Girshick Birgit | CEO, Dir | M - OptEx | $179.66 | +6,500 | 42.5K | +18% | +$1.17M |
| DT | 2026-08-13 16:37 | 2026-08-11 | CRL | Girshick Birgit | CEO, Dir | S - Sale+OE | $279.90 | -6,500 | 36.0K | -15% | -$1.82M |
| DT | 2026-08-13 16:37 | 2026-08-11 | CRL | Girshick Birgit | CEO, Dir | M - OptEx | $0.00 | -6,500 | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-08-11 | M | A | 6,500 | $179.66 | 42,513 | D | — | — | |
| 2 | Common | Common Stock | 2026-08-11 | S | D | 6,500 | $279.90 | 36,013 | D | — | — | (F1) This exercise and sale occurred pursuant to a Rule 10b5-1 Trading Plan that was initially adopted on March 3, 2025. |
| 3 | Derivative | Stock Options (Right to Buy) | 2026-08-11 | M | D | 6,500 | $0.00 | 0 | D | $179.66 · 2021-05-29 to 2030-05-29 | 6,500 Common Stock |